Mercer Global Advisors
CLYM

Mercer Global Advisors’s Climb Bio CLYM Stock Holding History

Mercer Global Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$704 Buy
+54
New +$558 ﹤0.01% 5778

Other funds holding CLYM

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mercer Global Advisors's CLYM Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Climb Bio (CLYM) in Q2 2026: 54 shares worth $704. The stake represents ﹤0.01% of the portfolio and ranks #5778 among its holdings.

55 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Mercer Global Advisors held 54 shares of Climb Bio worth $704 as of Q2 2026.
  • Climb Bio was a new Mercer Global Advisors position in Q2 2026.
  • Climb Bio made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5778 holding.
  • 55 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.